Compare Cardinal Health Inc (CAH) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs MobilEye Global Inc — how do they compare? Cardinal Health Inc trades at $236.04 (market cap $55.88B), while MobilEye Global Inc trades at $8.73 (market cap $7.54B). The key difference: Cardinal Health Inc is far larger — about 7.4× MobilEye Global Inc's market cap, and Cardinal Health Inc pays a 0.86% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.
| CAH | MBLY | |
|---|---|---|
Market Cap | $55.88B | $7.54B |
Sector | Health | Technology |
52-Week High | $240.26 | $15.54 |
52-Week Low | $146.04 | $6.56 |
Enterprise Value | $59.91B | $6.10B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.
Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.
Mobileye Global Inc. (MBLY) trades at $8.81, up 0.69% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings beats, driven by an R&D grant, though it remains unprofitable with a net income margin of -201.49%. Recent news highlights CEO transition plans and a new supply deal with Stellantis, while analyst consensus is bullish with a $11.40 price target.
The outlook is mixed: raised 2026 guidance and strategic partnerships offer growth potential in autonomous driving, but persistent losses, leadership changes, and high valuation multiples pose significant risks. Investors should weigh the company's technological positioning against its current financial health and execution challenges in a competitive market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
